Teva Pharmaceutical Industries Ltd. announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company?s manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Drapé will remain in his role until June 3, 2024.

Mr. Shields will be a member of Teva?s Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva?s U.S. headquarters in Parsippany, NJ. Mr. Shields, age 50 joins Teva with a track record over a 25-plus year career in the global biopharmaceutical and animal health industries.

As an engineer by trade, Mr. Shields brings significant experience at every stage of the manufacturing and supply process. Most recently, Mr. Shields served as Senior Vice President for Animal Health Manufacturing for Merck, known as MSD Animal Health outside of the United States and Canada, where he oversaw end-to-end manufacturing, supply chain, procurement, and process development. Prior to Merck, he led Specialty Care Manufacturing, Engineering, and Operational Excellence for Sanofi.

Mr. Shields spent much of his early career at Amgen, where held a variety of leadership roles in Operations. Mr. Shields is a manufacturing and supply chain leader with more than 25 years of experience in the biopharmaceuticals and animal health industries. He?s held leadership roles at Merck Animal Health, Sanofi, and Amgen.

He joins Teva from Merck Animal Health where he served as Senior Vice President for Manufacturing with responsibility for supporting $5.6 billion in annual sales. During his time at Merck, Mr. Shields also oversaw the Supply Chain, Procurement, and Process Development organizations. His leadership was instrumental in navigating challenging global issues and business integration efforts, while driving improvements in the company?s operations network and delivering significant savings.

Prior to Merck, Mr. Shields was a senior leader at Sanofi, first serving as Head of Engineering and Operational Excellence for the company?s Biologics organization. In that role, he led a lean transformation program resulting in substantial cost savings and operational efficiencies. Later he became Global Head of Sanofi?s Specialty Care Manufacturing organization with a focus on enabling the successful launches of Dupixent and Praluent, while also overseeing the commissioning and startup of Sanofi?s first digitally enabled continuous manufacturing facility.

Mr. Shields spent a significant portion of his career with Amgen, holding series of increasingly responsible leadership roles including Head of Global Raw Material Supplier Relationships, Executive Director & Plant Manager in Singapore, and Executive Director of Manufacturing. Notable achievements include overseeing the transition of Amgen?s manufacturing of the future program from R&D to Operations, the start-up of its manufacturing site of the future in Singapore, and leading capacity and throughput improvements of their large-scale biologics manufacturing facility in Rhode Island. Mr. Shields received his undergraduate degree in Chemical Engineering & Materials Science Engineering from the University of Connecticut and an MBA from Bryant University in Rhode Island.

He currently serves on the board of the National Association of Manufacturers.